Ms. Michelle Lefler reports

AURORA CANNABIS ANNOUNCES FILING OF PROSPECTUS SUPPLEMENT FOR AT-THE-MARKET OFFERING PROGRAM

Aurora Cannabis Inc. has filed a prospectus supplement establishing a new at-the-market offering program that allows the company to issue and sell up to $100-million (U.S.) of common shares in the capital of the Company (the "Common Shares") from treasury to the public, from time to time, at the company's discretion.

The company intends to use the net proceeds from the offering for strategic and accretive purposes only, including for increased cultivation capacity and M&A (mergers and acquisitions).

Any common share sales under the ATM program will be made through at-the-market distributions, as defined in National Instrument 44-102, Shelf Distributions, and sold through the Nasdaq Capital Market or another marketplace in the United States at the prevailing market price at the time of sale. Sales may also be made in privately negotiated transactions. No sales will be made through a stock exchange or stock market in Canada.

Distributions of the common shares through the ATM program will be made pursuant to the terms of a sales agreement dated Feb. 4, 2026, among the company and TD Securities (USA) LLC.

A prospectus supplement to the company's short-form base shelf prospectus dated Feb. 14, 2025, has been filed with the securities commissions or securities regulatory authorities in each of the provinces of Canada, except Quebec, and with the U.S. Securities and Exchange Commission (SEC) as part of the company's registration statement on Form F-10 under the U.S./Canada multijurisdictional disclosure system. The prospectus supplement, the base shelf prospectus and the registration statement contain important detailed information about the company and the ATM program. Prospective investors should read the prospectus supplement, the base shelf prospectus, the registration statement and the other documents the company has filed for more complete information about the company and the ATM offering before making an investment decision. Copies of the prospectus supplement and the base shelf prospectus are available on SEDAR+ and copies of the prospectus supplement and the registration statement will be available on EDGAR.

About Aurora Cannabis Inc.

Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance and a deep commitment to patient care. Aurora serves both medical and consumer markets across Canada, Europe, Australia and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach. Aurora's portfolio of trusted, leading brands includes Aurora, MedReleaf, Pedanios, IndiMed, San Raf, Tasty's and Whistler Cannabis Co. The company also holds a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. With world-class GMP-certified (good manufacturing practice) manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of opening the world to cannabis.

We seek Safe Harbor.